Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc., sold a total of 189,356 shares of common stock across three transactions in late October and early November 2025 through a pre-arranged 10b5-1 plan.

Summary

• Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), reported sales of common stock.
• The transactions occurred on October 30, 2025, October 31, 2025, and November 3, 2025.
• A total of 189,356 shares were sold across these three dates.
• The sales were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• On October 30, 2025, 55,795 shares were sold at a weighted average price of $1.43 per share.
• On October 31, 2025, 73,192 shares were sold at a weighted average price of $1.28 per share.
• On November 3, 2025, 60,369 shares were sold at a weighted average price of $1.29 per share.
• Following these transactions, the indirect beneficial ownership of common stock by entities associated with Luke Evnin decreased from 4,076,920 shares to 3,943,359 shares.
• The shares are held indirectly through various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• Luke Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner. While executed under a 10b5-1 plan, which suggests pre-planning, the sheer volume and the fact that an insider is reducing their stake can be interpreted as a lack of confidence in the company's near-term stock performance or future prospects.

Negatives

• Significant insider selling by a Director and 10% owner, totaling 189,356 shares.
• The sales occurred at relatively low weighted average prices ($1.43, $1.28, $1.29), which could suggest a lack of confidence in the near-term stock appreciation.
• The reduction in beneficial ownership by entities associated with a key insider may be perceived negatively by investors.

Risks

• Potential negative investor sentiment due to significant insider selling.
• The sales could signal a lack of confidence from a major shareholder and director regarding the company's future prospects or valuation.
• Increased selling pressure on the stock if other insiders or institutional investors follow suit.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This filing reports an insider stock sale, which is a routine disclosure for publicly traded companies. While not directly related to broader industry trends, significant insider selling in the biotechnology sector can sometimes be interpreted as a signal regarding the company's specific prospects within a competitive and capital-intensive industry.

Corporate Governance

Related Party Transactions

• The shares were sold by various MPM entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.) where Luke Evnin holds various management and membership roles.
• Luke Evnin disclaims beneficial ownership of the securities held by these entities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal, potentially leading to decreased confidence and selling pressure on the stock.

Next Steps

• The reporting person has committed to providing detailed transaction information upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

While the insider selling by a Director and 10% owner is a negative signal, the transactions were executed under a pre-arranged 10b5-1 plan, which suggests a planned diversification or liquidity event rather than an immediate reaction to adverse news. However, the significant volume of shares sold at relatively low prices warrants caution. Investors should 'hold' and monitor future company developments and insider activity closely, as this sale could indicate a perceived lack of significant upside in the near term.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, 10b5-1 Plan, Director, 10% Owner, Stock Sale, Biotechnology